denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Research, Biological therapies, Hodgkin lymphoma, clinical trials, Clinical Practice (Health Services and Quality), Non-Biological therapies, Lymphomas, Chemotherapy, Clinical Research, Checkpoint Inhibitor, Diseases, Therapies, Lymphoid Malignancies, Radiation Therapy, Transplantation
Description:
Classic Hodgkin lymphoma (cHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are distinct diseases with different treatment paradigms. cHL is an aggressive disease that is highly curable, therefore current research is focused on developing regimens that maintain or improve upon efficacy and also minimize treatment-related toxicity. Studies are beginning to demonstrate that incorporation of brentuximab vedotin (BV) or PD-1 blockade into the front-line or second line setting for cHL may aid in achieving this goal. NLPHL is typically an indolent disease associated with favorable outcomes; however there are certain features that can indicate risk for a more aggressive course. Given its variable presentation, treatment for NLPHL is individualized.
Dr. Alison Moskowitz will review the management of primary refractory/first relapsed Hodgkin lymphoma. She will discuss data supporting the use of novel agents in second-line treatment and studies exploring transplant-free approaches for relapsed and refractory disease.
Dr. Sven Borchmann will review the management of Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). He will put emphasis on the need for an individualized approach considering patient preferences, disease aggressiveness and individual host factors.
Dr. Alex Herrera will present the available data regarding the use of brentuximab vedotin and PD-1 blockade in the frontline management of Hodgkin lymphoma. He will discuss the current and potential future role of the novel agents in the initial management of HL and ongoing clinical trials that seek to define those roles.
Dr. Alison Moskowitz will review the management of primary refractory/first relapsed Hodgkin lymphoma. She will discuss data supporting the use of novel agents in second-line treatment and studies exploring transplant-free approaches for relapsed and refractory disease.
Dr. Sven Borchmann will review the management of Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). He will put emphasis on the need for an individualized approach considering patient preferences, disease aggressiveness and individual host factors.
Dr. Alex Herrera will present the available data regarding the use of brentuximab vedotin and PD-1 blockade in the frontline management of Hodgkin lymphoma. He will discuss the current and potential future role of the novel agents in the initial management of HL and ongoing clinical trials that seek to define those roles.